MENLO PARK, Calif.,
Nov. 10, 2014 /PRNewswire/ --
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company
focused on the development of novel drug delivery products to
address unmet needs in large, well-defined and underserved markets,
today announced the appointment of Mr. Ping
Wang, Principal of Korea Investment Partners, to the
company's board of directors. Mr. Wang's appointment follows
Korea Investment Partners' investment in BioPharmX as part of its
Series A private placement, which was also announced today.
"Having an accomplished professional like Mr. Wang join our
board is an asset to our company," said Jim
Pekarsky, chief executive officer and co-founder of
BioPharmX Corporation. "His expertise in guiding emerging
growth companies will prove essential as we move our pipeline of
products through clinical development toward global
commercialization."
Prior to joining Korea Investment Partners in 2010, Mr. Wang
worked at Great Pacific Financial Group, where he was in charge of
asset management and structured financing. Previously, Mr.
Wang was an investment officer at Beijing Ancai Technology Venture
Capital, and earlier, worked at Matsuoka Industry Group as IT
Manager where he set up Shanghai Shangsoft. He began his
professional career as a software engineer at IBM. Mr. Wang
earned a B.S. degree in Computer Science at the University of Texas, Austin, and graduated from the
MIT Sloan-Tsinghua joint program with an International MBA
degree.
About BioPharmX Corporation
BioPharmX Corporation
(OTCQB: BPMX) is a Silicon Valley-based biotechnology company,
which seeks to provide innovative products through unique,
proprietary platform technologies for prescription,
over-the-counter ("OTC"), and supplement applications in the
fast-growing health and wellness markets, including women's health,
dermatology, and otolaryngology (ears, nose & throat). To
learn more about BioPharmX, visit www.BioPharmX.com.
About Korea Investment Partners
Korea Investment
Partners (KIP), a Korea Investment Holdings company, is a private
equity company specializing in small- and mid-cap businesses and
has been discovering, investing in and promoting the growth of
promising businesses since establishment in 1986. Since 2000, KIP
has been managing venture capital funds worth KRW 907.3 billion and an overseas fund worth
RMB 100 million while maintaining
robust relationships with major long-term institutional investors
including National Pension Service, Korea Finance Corporation and
Korea Development Bank based on its solid track record. To
learn more about Korea Investment Partners, visit
www.kipvc.com.
Forward-Looking Statements
Statements in this news
release relating to the business of BioPharmX, which are not
historical facts, are "forward-looking statements." These
forward-looking statements may be identified by words such as
"expect," "anticipate," "believe," or similar expressions that are
intended to identify such forward-looking statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement and the risks and other
factors detailed in the company's filings with the Securities and
Exchange Commission (SEC). Given these risks and uncertainties, you
are cautioned not to place undue reliance on such forward-looking
statements. The forward-looking statements included in this news
release are made only as of the date hereof and the company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities law.
[Editor's note: See also today's news release entitled,
"BioPharmX Corporation Secures Up To $12
Million In Private Placement"]
BioPharmX is a trademark of BioPharmX Corporation.
SOURCE BioPharmX Corporation